CFSAN Priorities: Industry & Consumer Groups Weigh In On NDIs And More
This article was originally published in The Tan Sheet
Executive Summary
FDA should accept safety findings from outside expert panels when reviewing new dietary ingredient notifications, CHPA says in Aug. 25 comments on CFSAN priorities
You may also be interested in...
Synthetics Stance In NDI Guidance Raises Red Flag For Industry
FDA's draft guidance on new dietary ingredient notifications already is arousing fierce pushback from the supplement industry over what constitutes an NDI and which substances cannot be dietary ingredients at all.
FDA Proposes Rule On Gluten-Free Labeling
Food products with "gluten-free" claims will be misbranded if they do not meet the conditions of a proposed rule FDA published in the Jan. 23 Federal Register
FDA Requiring GRAS-Level Safety Standards For NDI Submissions, Experts Say
FDA has gradually raised the safety standard for new dietary ingredients above the level intended by DSHEA, according to several experts